Iron Deficiency in Polycythemia Vera: Mechanisms and Clinical Significance
Iron deficiency in polycythemia vera (PV) occurs due to the massive consumption of iron by the hyperproliferative erythroid clone, which depletes body iron stores despite the paradoxical presence of elevated red blood cell mass. This creates a physiological disconnect where patients simultaneously have too many red cells yet insufficient iron to sustain ongoing erythropoiesis 1.
Primary Mechanisms
The iron deficiency in PV results from several interconnected pathways:
Increased Iron Consumption
The JAK2-mutated erythroid clone drives autonomous, uncontrolled red blood cell production that consumes iron at rates far exceeding normal erythropoiesis. This hyperproliferative state creates a functional iron deficiency where iron is rapidly incorporated into hemoglobin, depleting circulating and storage iron pools 1.
Dysregulated Hepcidin Signaling
PV patients demonstrate inappropriately low hepcidin levels relative to their iron-deficient state 1, 2. Normally, iron deficiency suppresses hepcidin to enhance iron absorption and mobilization. However, in PV:
- The erythroid hyperplasia produces excessive erythroferrone, which suppresses hepcidin
- Despite low serum ferritin, hepcidin remains insufficiently suppressed to correct the iron deficiency
- This suggests hepcidin regulation is fundamentally disordered in PV pathobiology 1
- Chronic inflammation in PV may partially counteract hepcidin suppression, though the relatively low ferritin levels indicate inflammation is not the dominant factor 1
Therapeutic Phlebotomy
Phlebotomy, the cornerstone treatment for maintaining hematocrit <45% in PV, directly removes iron-containing red cells and significantly exacerbates iron deficiency 3, 1. Each phlebotomy removes approximately 200-250 mg of iron.
Additional Contributing Factors
- Chronic gastrointestinal bleeding (from aspirin therapy or disease-related factors)
- Potential defects in iron absorption (not fully elucidated)
- Aberrant hypoxia sensing and signaling pathways 1
Clinical Prevalence and Diagnostic Utility
Iron deficiency occurs in approximately 53% of PV patients, compared to only 1.32% in secondary polycythemia 4. This striking difference makes iron deficiency a highly specific marker:
- Sensitivity: 52.63%
- Specificity: 100% for distinguishing PV from secondary polycythemia 4
The presence of iron deficiency in a patient with polycythemia should strongly raise suspicion for PV rather than secondary causes 4.
Clinical Consequences
Iron deficiency in PV contributes to significant symptom burden beyond hematologic parameters:
Importantly, iron-deficient red cells demonstrate reduced deformability and increased fragility 6. This altered membrane rheology may:
- Contribute to shortened red cell survival
- Potentially increase thrombotic risk, as thrombotic events appear more frequent with depleted iron stores 6
- Cause paradoxical hyperviscosity despite lower hemoglobin levels
Diagnostic Considerations
Per WHO guidelines, hemoglobin levels are expected to be lower in the presence of iron deficiency, which confounds accurate interpretation of diagnostic criteria 3. The guidelines specify:
- For research or clinical trials, formal PV diagnosis requires demonstrating WHO criteria are met after iron replacement
- In routine clinical practice, clinicians should not be prevented from making a working diagnosis of PV in the presence of iron deficiency, even if WHO hemoglobin/hematocrit thresholds are not met 3
This pragmatic approach recognizes that iron deficiency may mask the full erythrocytotic potential of PV.
Management Implications
Cytoreductive therapy (hydroxyurea, ruxolitinib, ropeginterferon) works more effectively to reverse PV-associated symptoms in iron-deficient patients compared to iron-replete patients 1. This paradoxical observation suggests:
- Iron deficiency may partially limit the erythrocytotic drive
- Cytoreduction combined with iron-restricted erythropoiesis provides additive disease control
Emerging Therapeutic Approaches
Novel strategies targeting iron metabolism are under investigation 5, 7:
- Hepcidin mimetics to restrict iron availability to the erythroid clone
- Ferroportin inhibitors to limit iron mobilization
- These approaches aim to improve quality of life and potentially reduce cytoreductive therapy needs in low-risk patients
Critical Caveat
Iron supplementation in PV is generally contraindicated as it would fuel the hyperproliferative erythroid clone, worsening polycythemia and potentially increasing thrombotic risk. The exception is when iron replacement is needed to confirm PV diagnosis per WHO criteria in research settings 3.